Business Context and Reporting Period
Company: DaVita Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 2, 2006
Event: Entry into a Material Definitive Agreement with Amgen USA Inc.
Key Financial Metrics
This filing does not contain specific financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics. The document focuses exclusively on the terms of a new supply agreement.
Material Changes
On February 2, 2006, DaVita Inc. entered into a new Dialysis Organization Agreement with Amgen USA Inc., replacing two prior agreements that expired on January 31, 2006. Key changes include:
- Product Scope: The agreement covers the purchase of Epoetin alfa (EPOGEN) and Darbepoetin alfa (Aranesp), which are used to treat dialysis patients.
- Supplier Status: Amgen remains the sole supplier of these products.
- Transition Period: A temporary letter agreement was in effect from January 31, 2006, to February 2, 2006, to maintain pricing continuity between the expiration of prior contracts and the new agreement.
- Term: The new agreement runs from February 3, 2006, through December 31, 2007.
Guidance, Outlook, and Management Commentary
The agreement establishes a framework for discount pricing, rebates, and incentives. These financial benefits are contingent upon DaVita meeting specific qualification requirements, including:
- Patient outcomes targets.
- Process improvement targets.
- Data submission targets.
- Volume growth of product purchases.
The filing does not provide specific forward-looking financial guidance, risk factors beyond the performance-based nature of the rebates, or details on unusual items.
Investor Verification Checklist
- Verify the specific discount rates and rebate structures defined in the full text of the Dialysis Organization Agreement.
- Assess the feasibility of meeting the patient outcomes and volume growth targets required to secure incentives.
- Monitor the impact of the new pricing terms on DaVita's cost of goods sold and gross margins in subsequent quarterly reports.
- Confirm the expiration date of the agreement (December 31, 2007) to evaluate future renewal risks.